Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Define in Preclinical Diastolic Dysfunction (PDD) With Renal Dysfunction, the Cardiorenal and Humoral Actions of Chronic Type V Phosphodiesterase (PDEV) Inhibition

Next Previous
Trial Profile

Define in Preclinical Diastolic Dysfunction (PDD) With Renal Dysfunction, the Cardiorenal and Humoral Actions of Chronic Type V Phosphodiesterase (PDEV) Inhibition

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Kidney disorders; Left ventricular dysfunction
  • Focus Pharmacodynamics
  • Acronyms Aim3

Most Recent Events

  • 15 Jan 2020 Status changed from recruiting to completed.
  • 20 Mar 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
  • 20 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top